These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30097256)

  • 1. Enhanced treatment of lung cancer by metronomic therapy with oral pemetrexed.
    Park K
    J Control Release; 2018 Aug; 284():250-251. PubMed ID: 30097256
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer.
    Mahmud F; Jeon OC; Alam F; Maharjan R; Choi JU; Park J; Lee S; Park JW; Lee DS; Byun Y
    J Control Release; 2018 Aug; 284():160-170. PubMed ID: 29908222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.
    Lal R; Hillerdal GN; Shah RN; Crosse B; Thompson J; Nicolson M; Vikström A; Potter VA; Visseren-Grul C; Lorenzo M; D'yachkova Y; Bourayou N; Summers YJ
    Lung Cancer; 2015 Aug; 89(2):154-60. PubMed ID: 26101013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pemetrexed for Treatment of Nonsquamous Non-Small-Cell Lung Cancer].
    Omori Y; Enatsu S
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1609-1613. PubMed ID: 30449848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
    Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
    Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
    Zhong A; Xiong X; Shi M; Xu H
    Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
    Takagi Y; Hosomi Y; Nagamata M; Watanabe K; Takahashi S; Nakahara Y; Yomota M; Sunami K; Okuma Y; Shimokawa T; Okamura T
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):559-64. PubMed ID: 26821156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
    Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
    Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management.
    Mahmud F; Chung SW; Alam F; Choi JU; Kim SW; Kim IS; Kim SY; Lee DS; Byun Y
    J Control Release; 2017 Mar; 249():42-52. PubMed ID: 28093298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
    Liang Y; Wakelee HA; Neal JW
    Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer].
    Zhang S; Liu J; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):232-9. PubMed ID: 25936888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
    Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
    BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity.
    Maharjan R; Subedi L; Pangeni R; Jha SK; Kang SH; Chang KY; Byun Y; Choi JU; Park JW
    Drug Deliv; 2021 Dec; 28(1):2313-2328. PubMed ID: 34730056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Chen CY; Lin JW; Huang JW; Chen KY; Shih JY; Yu CJ; Yang PC
    Clin Lung Cancer; 2015 Nov; 16(6):e131-40. PubMed ID: 25659505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed disodium for the treatment of NSCLC: an update.
    Hsu JY; Wakelee H
    Drugs Today (Barc); 2008 Sep; 44(9):669-78. PubMed ID: 19137122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
    Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
    Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized eczema craquelé (asteatotic dermatitis) associated with pemetrexed treatment.
    Chu CH; Chou CY; Lin FL
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e81-e83. PubMed ID: 26416293
    [No Abstract]   [Full Text] [Related]  

  • 18. Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
    Hata A; Katakami N; Hattori Y; Tanaka K; Fujita S; Kotani Y; Nishimura T; Imamura F; Yokota S; Satouchi M; Monden K; Otsuka K; Nishiyama A; Tsubouchi K; Kaneda T; Yoshioka H; Morita S; Negoro S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):689-695. PubMed ID: 28280972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
    Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
    Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.